Lauzon Armand F Jr
CIK: 0001753173
Lauzon Armand F Jr's purchase track record
Lauzon Armand F Jr has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/8/2023 | ROG | $503K | -19.7% | -22.2% | +10.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ROG | ▲ Buy | Grant | 1,427 | $0 | 5/6/2026 | View on chart |
| ROG | ▲ Buy | Grant | 2,760 | $0 | 5/5/2025 | View on chart |
| ROG | ▲ Buy | Grant | 1,500 | $0 | 5/2/2024 | View on chart |
| ROG | ▲ Buy | Open Market | 3,350 | $503K | 8/8/2023 | View on chart |
| ROG | ▲ Buy | Grant | 950 | $0 | 5/4/2023 | View on chart |
| ROG | ▲ Buy | Grant | 200 | $0 | 3/9/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Roche presents new Phase III data and FDA approval
Roche reported new one-year Phase III data for vamikibart in treating uveitic macular edema, a condition causing vision loss. Additionally, the FDA approved Tecentriq for adjuvant treatment of stage III colon cancer. These developments reflect ongoing progress in the company's clinical pipeline and regulatory approvals.
Roche presents new Phase III data and FDA approval. Roche reported new one-year Phase III data for vamikibart in treating uveitic macular edema, a condition causing vision loss. Additionally, the FDA approved Tecentriq for adjuvant treatment of stage III colon cancer. These developments reflect ongoing progress in the company's clinical pipeline and regulatory approvals.